This week on Pharm5:

• Ivermectin fails against COVID-19


• Cabenuva noninferior to Biktarvy


• Syfovre for geographic atrophy


• Aspirin for pre-eclampsia prevention


• TRUNCATE-TB results could shorten TB treatment

Connect with us!

• Listen to our podcast: Pharm5


• Follow us on Twitter: @LizHearnPharmD

References:

1. Naggie S, Boulware DR, Lindsell CJ, et al. Effect of higher-dose ivermectin for 6 days vs placebo on time to sustained recovery in outpatients with covid-19. JAMA. February 2023. doi:10.1001/jama.2023.1650.


2. Efficacy: Cabenuva (cabotegravir; Rilpivirine). Efficacy: Every 2 Month | CABENUVA Official HCP Website. http://bit.ly/3kpnkdU. Accessed February 23, 2023.


3. VIIV healthcare announces positive data demonstrating long-acting injectable Cabenuva (cabotegravir, Rilpivirine) is as effective as daily oral biktarvy (BIC/FTC/TAF) for the treatment of HIV-1. ViiV Healthcare. http://bit.ly/3m14uKy. Accessed February 23, 2023.


4. Low-dose aspirin use for the prevention of preeclampsia and related morbidity and mortality. ACOG. http://bit.ly/3kuekE7. Accessed February 23, 2023.


5. Mendoza M, Bonacina E, Garcia-Manau P. Aspirin discontinuation at 24 to 28 weeks’ gestation in pregnancies a high risk of preterm preeclampsia:


6. a randomized clinical trial. JAMA. February 2023. doi: 10.1001/jama.2023.0691.


7. FDA Oks first drug for geographic atrophy, a major cause of adult blindness. FDA OKs First Drug for Geographic Atrophy, a Major Cause of Adult Blindness. http://bit.ly/3ZgFwoE. Published February 17, 2023. Accessed February 22, 2023.


8. Paton NI, Cousins C, Suresh C, et al. Treatment strategy for rifampin-susceptible tuberculosis. New England Journal of Medicine. 2023. doi:10.1056/nejmoa2212537


9. Treatment for TB disease. Centers for Disease Control and Prevention. http://bit.ly/3Y5HxTW. Published March 7, 2022. Accessed February 23, 2023.